In a research in breast cancer cells, the combination of lapatinib, a dual HER2/neu and EGFR tyrosine kinase inhibitor, with INK128 prevented the two HER2 and HER3 phosphorylation induced by INK128 and made synergistic induction of mobile Demise in several HER2-beneficial mobile strains resistant to trastuzumab and lapatinib. In vivo https://peteri554ewo5.scrappingwiki.com/user